Modern antiretroviral regimens in pregnant women: virologic outcomes and durability.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
pubmed:
8
6
2023
medline:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Data are lacking on the virologic efficacy and durability of modern antiretroviral treatment (ART) regimens during pregnancy. We compared virologic outcomes at delivery among women receiving dolutegravir versus other ART and the rate of change of the initial pregnancy regimen. Single-site retrospective cohort between 2009 and 2019. We used univariable and multivariable generalized estimating equations to model the relationship between the maternal ART anchor and the proportion of women with a detectable viral load (greater than or equal to 20 HIV RNA copies/mL of plasma) closest to delivery (suboptimal virologic control) and with a detectable viral load at any time in the third trimester. We also compared changes in ART during pregnancy. We evaluated 230 pregnancies in 173 mothers. Rates of optimal virologic control at delivery did not significantly differ in mothers who received dolutegravir (93.1%), rilpivirine (92.1%), boosted darunavir (82.6%), or efavirenz (76.9%) but were significantly lower among mothers receiving atazanavir (49.0%) or lopinavir (40.9%). The odds of having a detectable viral load at any time in the third trimester was also higher for atazanavir and lopinavir. Raltegravir, elvitegravir, or bictegravir were used in less than 10 mothers at delivery, which precluded statistical analyses. The frequency of change in ART was significantly higher in mothers who initially received elvitegravir (68%) or efavirenz (47%) than dolutegravir (18%). Dolutegravir-containing, rilpivirine-containing, and boosted darunavir-containing regimens conferred excellent virologic control in pregnancy. Atazanavir and lopinavir, elvitegravir, and efavirenz were associated with either high rates of virologic failure or regimen change during pregnancy.
Identifiants
pubmed: 37289582
doi: 10.1097/QAD.0000000000003616
pii: 00002030-990000000-00274
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-29Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mandelbrot L, Tubiana R, Le Chenadec J, Dollfus C, Faye A, Pannier E, et al. ANRS-EPF Study Group. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception . Clin Infect Dis 2015; 61:1715–1725.
Townsend CL, Byrne L, Cortina-Borja M, Thorne C, de Ruiter A, Lyall H, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011 . AIDS 2014; 28:1049–1057.
Benamor Teixeira ML, Fuller TL, Fragoso Da Silveira Gouvea MI, Santos Cruz ML, Ceci L, Pinheiro Lattanzi F, et al. Efficacy of three antiretroviral regimens initiated during pregnancy: clinical experience in Rio de Janeiro . Antimicrob Agents Chemother 2020; 64:e01068-20.
Pascom ARP, Fonseca FF, Pinho RGG, Perini FB, Pereira G, Avelino-Silva VI. Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil . Int J STD AIDS 2020; 31:903–910.
Joao EC, Morrison RL, Shapiro DE, Chakhtoura N, Gouvea MIS, de Lourdes BTM, et al. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial . Lancet HIV 2020; 7:e322–e331.
Brites C, Nobrega I, Luz E, Travassos AG, Lorenzo C, Netto EM. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women . HIV Clinical Trials 2018; 19:94–100.
Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study) . PLoS Med 2019; 16:e1002895.
Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, et al. DolPHIN-2 Study Group. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial . Lancet HIV 2020; 7:e332–e339.
Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, et al. IMPAACT 2010/VESTED Study Team and Investigators. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial . Lancet Infect Dis 2021; 397:1276–1292.
World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. 2019. Available at https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15 .
Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at https://clinicalinfo.hiv.gov/en/guidelines/perinatal .
Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, et al. Dolutegravir in pregnancy as compared with current HIV regimens in the United States . N Engl J Med 2022; 387:799–809.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support . J Biomed Inform 2009; 42:377–381.
Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, et al. IMPAACT 1026s study team. Raltegravir pharmacokinetics during pregnancy . J Acquir Immune Defic Syndr 2014; 67:375–381.
Momper JD, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. IMPAACT P1026s Protocol Team. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV . AIDS 2018; 32:2507–2516.
Bukkems VE, Hidalgo-Tenorio C, Garcia C, van Hulzen AGW, Richel O, Burger DM, Colbers AP. Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) network. First pharmacokinetic data of bictegravir in pregnant women living with HIV . AIDS 2021; 35:2405–2406.
Rahangdale L, Cates J, Potter J, Badell ML, Seidman D, Miller ES, et al. HOPES (HIV OB Pregnancy Education Study) Group. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction . Am J Obstet Gynecol 2016; 214:385.e1–385.e7.
Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, et al. ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial . Lancet Infect Dis 2011; 378:238–246.
Nakalema S, Chappell CA, Pham M, Byakika-Kibwika P, Kaboggoza J, Walimbwa SI, et al. Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy . J Antimicrob Chemother 2022; 77:3144–3152.
Scarsi K, Lamorde M, Darin K, Penchala SD, Else L, Nakalema S, et al. Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant . J Int AIDS Soc 2014; 17: (4 Suppl 3): 19484.
Rimsky L, Vingerhoets J, Van Eygen V, Eron J, Clotet B, Hoogstoel A, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis . J Acquir Immune Defic Syndr 2012; 59:39–46.
Chaussade H, Tumiotto C, Le Marec F, Leleux O, Lefevre L, Lazaro E, et al. A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long-term use of darunavir in people with HIV. The ANRS CO3 Aquitaine Cohort . Open Forum Infect Dis 2020; 7:ofaa567.
Yoshinaga T, Miki S, Kawauchi-Miki S, Seki T, Fujiwara T. Barrier to resistance of dolutegravir in two-drug combinations . Antimicrob Agents Chemother 2019; 63:e02104-18.
Boyd SD, Sampson MR, Viswanathan P, Struble KA, Arya V, Sherwat AI. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint . AIDS 2019; 33:1089–1093.